Good Biotech Corp. is a fully integrated biotechnology company that develops, manufactures, and commercializes of Duck IgY (ΔFc) antibodies from duck egg yolks for the uses of diagnostics and therapeutics. The company is the one and only one manufacturer in the world which has unprecedented success of building up the novel duck IgY(ΔFc) antibody technology platform. This proprietary technology has been validated through various products, such as IgY(ΔFc) antibody based new immunoturbidimetric assay kits (with FDA 510(k) cleared), reagents for life science research, and IgY(ΔFc) antibody based biotherapeutics. Based upon the cutting edge technology and the unique characteristics of duck IgY(ΔFc) antibody, Good Biotech has gained promising results on the development of duck IgY(ΔFc) antibody derived Biotherapeutics & Functional Health Foods, including but not limited to Snake Antivenom immunoglobilins, Digoxin Immune Fab, Neutralizing IgY(ΔFc) Antibodies to MDR bacteria (e.g. for the treatment of Nosocomial Infections), anti-Caries, anti-Obesity, Gastrointestinal Health Care Products. We primary focus on the research and development efforts in the core application areas of the unique IgY(ΔFc) antibody listed below and are pursuing more products for these therapeutic areas.
Unmet Medical Needs
Equine and ovine based polyclonal antibodies are the major source for antivenoms, antitoxin (eg. anti-Rabies Immunoglobulins) and antidotes (e.g. digoxin antidote) at present. However, both equine/ovine based biologicals suffer from lower efficacy, low productivity, high production costs, and the potential of life-threatening allergic reactions and/or biohazard risk. Therefore, many equine/ovine based biologicals are still in shortage and with an urgent need. Unlike classical equine/ovine based biologicals, production IgY (△Fc) antibody based biotherapeutics in hyper immune duck eggs possesses the advantages including higher neutralizing activity, excellent productivity, lower production cost, simpler downstream processing, fast/mass production, and free from allergenicity/ biohazard risk of TSE. Production of duck IgY(ΔFc) antibodies is cost effective, conforming to the expectation of animal protection organizations; and is timely in view of the World Health Organization’s (WHO) current initiative to review the quality, efficacy, safety, and affordable therapeutic antibodies. Thus, it is expected that IgY(ΔFc) derived next generation Biotherapeutics will play a pivotal role and contribute the popularity of specialty biopharmaceuticals which address to high unmet medical needs.
Good Biotech concentrates on developing innovative IgY(ΔFc) antibody derived Biotherapeutics as acute/critical care specialty pharmaceutical products that address serious disease in the areas of significant unmet medical need. The products currently available for partnering are as follows; click on each product for more information.
We seek to collaborate with leading global pharmaceutical companies with a proven track record in clinical experience, for completion of the final phases of the clinical trials, and commercial capabilities, to successfully bring our innovative developments to market. We believe that this is the way to combine our drug development expertise with your commercial development capabilities.
Are you a potential partner?
If you are interested in exploring a potential partnership, please contact us at: email@example.com